How Circadian Rhythms Can Change PK and Safety Readouts

We tend to think of time in terms of study days, periods and sampling points when it comes to the world of clinical pharmacology. Human physiology thinks about time differently. Nearly every system that touches a drug, from the gut to the liver to the kidney, follows a roughly 24-hour rhythm. If a protocol does […]

How Data Standardization Supports Faster Regulatory Review

Every sponsor wants the same thing at the end of a clinical program: a submission that reviewers can open, understand, and act on quickly. Often the biggest obstacle is not the science, but the data. Datasets built with inconsistent structures, naming conventions, and terminology slow review, trigger information requests, and can put a submission’s timeline […]

How CRO Infrastructure Impacts Inspection Outcomes

When sponsors evaluate a contract research organization (CRO), discussions often focus on timelines, enrollment capabilities, therapeutic expertise, and cost. While these factors are important, there is another consideration that can have a lasting impact on study success: infrastructure. A CRO’s infrastructure extends far beyond its physical facilities. It encompasses the systems, processes, technology, personnel, quality […]

Planning Seamless Transitions From Phase I to Phase II

Completing a Phase I study is a milestone, but for sponsors the harder work often comes next. Moving from first-in-human data to a well-designed Phase II program is where timelines slip, budgets stretch, and promising compounds lose momentum. Most of these delays aren’t scientific failures. They come from gaps in planning, data continuity, and operational […]

Managing Food Effect Studies in Modern Bioequivalence Programs

For many orally administered drug products, what happens after a patient takes a dose can depend heavily on whether they have recently eaten a meal. Food can alter how a drug is absorbed, how quickly it reaches circulation, and ultimately how it performs in the body. Understanding these effects is a critical component of drug […]

How CRO Infrastructure Impacts Inspection Outcomes

When sponsors evaluate a contract research organization (CRO), discussions often focus on timelines, enrollment capabilities, therapeutic expertise, and cost. While these factors are important, there is another consideration that can have a lasting impact on study success: infrastructure. A CRO’s infrastructure extends far beyond its physical facilities. It encompasses the systems, processes, technology, personnel, quality […]

The Role of Centralized Monitoring in Early Phase Risk Management

By: Dr. Michelle Radke (AXIS – Medical Principal Investigator) Early phase studies move fast, and the margin for error is thin. A single ascending dose cohort can generate safety data such as clinical labs, vital signs, ECGs, and adverse events, along with PK samples, all of which must be reviewed, reconciled, and acted on before […]

Managing Food Effect Studies in Modern Bioequivalence Programs

For many orally administered drug products, what happens after a patient takes a dose can depend heavily on whether they have recently eaten a meal. Food can alter how a drug is absorbed, how quickly it reaches circulation, and ultimately how it performs in the body. Understanding these effects is a critical component of drug […]

When Adaptive Design Works (And When It Doesn’t): A Sponsor’s Early Phase Decision Guide

Early phase development has always demanded speed and rigor-sometimes in tension. Today, sponsors face a new pressure: the complexity of molecules and the crowded competitive landscape mean that a 12-month Phase I no longer feels optional; it feels like a competitive disadvantage. Adaptive designs are reshaping how we approach this tradeoff. In their place, adaptive […]

Have questions or need expert support? Our team is here to help—reach out and let’s move forward together.

Get In Touch